Brief: Arch Biopartners Receives Funding For Development Of LSALT Peptide Drug Program
23/03/2023 11:18
March 23 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS RECEIVES FUNDING FOR DEVELOPMENT OF LSALT
PEPTIDE DRUG PROGRAM
* ARCH BIOPARTNERS - RECEIVING ADVISORY SERVICES, UP TO $4
MILLION
IN FUNDING FROM NATIONAL RESEARCH COUNCIL OF CANADA INDUSTRIAL
RESEARCH ASSISTANCE PROGRAM
Source text for Eikon: ID:nGNX53PCB3
Further company coverage: ARCH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide